Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID ALBERT GREMSE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Gastroenterology

NPI
1750369468
CMS profile
306691
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$271.66

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $271.66 12

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID ALBERT GREMSE

NPI 1750369468 · CMS profile ID 306691

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Gastroenterology

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750369468?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID ALBERT GREMSE, NPI 1750369468, CMS profile ID 306691. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750369468?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID ALBERT GREMSE, NPI 1750369468, CMS profile ID 306691. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750369468?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID ALBERT GREMSE, NPI 1750369468, CMS profile ID 306691, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1750369468?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $271.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $25.5012/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049751547 CMS
Eisai Inc. $16.8911/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023307073 CMS
Rhythm Pharmaceuticals, Inc. $20.0111/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051225291 CMS
Regeneron Healthcare Solutions, Inc. $23.4210/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999195137 CMS
Cumberland Pharmaceuticals, Inc. $13.5210/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052116703 CMS
GENZYME CORPORATION $25.5009/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049751457 CMS
Alcresta Therapeutics, Inc. $21.8008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039088967 CMS
Cumberland Pharmaceuticals, Inc. $13.7708/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052116697 CMS
GENZYME CORPORATION $27.4605/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049751419 CMS
Alcresta Therapeutics, Inc. $31.3504/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039088963 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.1803/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055395627 CMS
Regeneron Healthcare Solutions, Inc. $31.2602/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999195133 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $174.48 6
PY2022 $374.29 14
PY2023 $271.66 12
PY2024 $1,739.94 20
PY2025 $376.03 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $198,587.61 104
PY2024 Principal investigator $217,659.62 148
PY2023 Principal investigator $97,220.00 54
PY2022 Principal investigator $32,000.00 10
PY2021 Recipient $6,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ferring International Pharmascience Center US $1,047.00 12/28/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $273.00 12/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272945
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 12/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,129.00 12/11/2025 Non-covered Recipient Entity
WCG IRB
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223289564
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,719.00 12/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 12/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272933
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 12/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 12/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272937
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 12/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 12/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272941
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 12/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272943
Principal investigator 1 AstraZeneca AB $3,514.00 12/03/2025 Non-covered Recipient Entity
SOUTH ALABAMA MED SCIENCE FOUND
A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age No dispute reported 06/30/2026 1185547351
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $42.62 12/03/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 12/01/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272923
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 12/01/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 12/01/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272927
Principal investigator 1 Ferring International Pharmascience Center US $37,826.00 11/28/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059661
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,658.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,658.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,621.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,621.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272915
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $486.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,758.00 11/12/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 10/08/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 10/08/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,261.00 10/08/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272899
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 10/08/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272901
Principal investigator 1 Ferring International Pharmascience Center US $19,511.00 09/28/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059648
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $91.00 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272881
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,053.10 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272891
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.80 09/25/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $91.00 09/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 09/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 09/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 09/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 09/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272873
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 09/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272875
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 09/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272877
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,621.00 09/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272857
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,658.00 09/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272859
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 09/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272861
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 09/10/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272863
Principal investigator 1 Ferring International Pharmascience Center US $952.00 08/28/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $91.00 08/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272855
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,408.00 08/06/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272853
Principal investigator 1 Ferring International Pharmascience Center US $4,783.00 08/01/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059623
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 07/09/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272849
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,355.00 07/09/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272851
Principal investigator 1 Ferring International Pharmascience Center US $2,985.10 07/01/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059615
Principal investigator 1 Ferring International Pharmascience Center US $5,457.67 06/23/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,658.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272833
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,719.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,163.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272837
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272839
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $486.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272841
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,621.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,719.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272845
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 06/11/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272847
Principal investigator 1 Ferring International Pharmascience Center US $9,445.00 06/03/2025 Non-covered Recipient Entity
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years No dispute reported 06/30/2026 1242059601
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $186.32 06/02/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 05/27/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272829
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $182.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272809
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $554.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272811
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272815
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272817
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $274.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272819
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272821
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272825
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 05/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 04/16/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272801
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 04/16/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272803
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 04/16/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272805
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,621.00 04/09/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272793
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,658.00 04/09/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272795
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $484.00 04/09/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,261.00 04/09/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272799
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 03/19/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,719.00 03/03/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 03/03/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272789
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $364.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272769
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,851.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $554.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $82.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $98.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272779
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $55.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $218.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $464.00 02/14/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272785
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,719.00 01/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $499.00 01/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,608.00 01/15/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE-BLIND, 12 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH SYMPTOMATIC NONEROSIVE GASTROESOPHAGEAL REFLUX DISEASE No dispute reported 06/30/2026 1223272767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,758.00 01/13/2025 Covered Recipient Teaching Hospital
USA HEALTH UNIVERSITY HOSPITAL
A PHASE 2, DOUBLE BLIND, UP TO 40 WEEK, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF DAILY ORAL ADMINISTRATION OF DEXLANSOPRAZOLE DELAYED-RELEASE CAPSULES FOR HEALING OF EROSIVE ESOPHAGITIS (EE) AND MAINTENANCE OF HEALED EE IN PEDIATRIC SUBJECTS AGED 1 TO 11 YEARS WITH EE No dispute reported 06/30/2026 1223272761